Myelodysplastic Syndrome
News
Azacitidine now available in China
Azacitidine for injection (Vidaza®) is now available in China. The nucleoside metabolic inhibitor was approved in China to treat patients with...
From the Journals
Sotatercept promising for treatment of anemia in MDS
The phase 2 trial included patients who did not respond to erythropoiesis-stimulating agents.
Conference Coverage
RELAZA2: MRD-guided azacitidine reduces relapse risk in MDS and AML
MRD-guided azacitidine therapy reduces hematological relapse in patients with MDS or AML at high risk for relapse, according to RELAZA2 trial...
News
Predicting response to AZA in MDS, CMML
Researchers have developed a technique that may help predict whether patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic...
Conference Coverage
Novel JAK1 inhibitor shows promise for myeloid malignancies
ATLANTA – A novel JAK1 inhibitor shows encouraging activity, particularly with azacitidine, in certain patients with advanced myeloid malignancies...
Conference Coverage
Avapritinib yields high response rate in patients with systemic mastocytosis
ATLANTA – Avapritinib was well tolerated in the phase 1 trial, and demonstrated encouraging preliminary activity.
News
FDA grants drug orphan designation for AML, MDS
The US Food and Drug Administration (FDA) has granted orphan drug designation to AMV564, a CD33/CD3 bispecific antibody, for the treatment of...
News
Rigosertib produces better OS in MDS than tAML
Rigosertib has demonstrated activity and tolerability in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia transformed from...
News
Generic azacitidine approved in Canada
Health Canada has approved Dr.
News
FDA approves first Erdheim-Chester disease treatment
Vemurafenib is now approved to treat ECD patients with the BRAF V600 mutation.
News
Drug receives fast track designation for lower-risk MDS
The US Food and Drug Administration (FDA) has granted fast track designation to the telomerase inhibitor imetelstat. The designation is for...